KIR2DL5B: A Potential Drug Target for Immune and Neurodegenerative Diseases

Target Name: KIR2DL5B

NCBI ID: G553128

KIR2DL5B

Other Name(s): Killer cell immunoglobulin-like receptor 2DL5B | Killer cell Ig-like receptor | killer Ig receptor | KIR2DLX | killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5B | putative killer cell immunoglobulin-like receptor like protein KIR3DP1-like | CD158 antigen-like family member F2 | killer-cell Ig-like receptor | killer cell immunoglobulin-like receptor 2DL5 | KIR2DL5 | killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5B | CD158f2 | KI2LB_HUMAN | KIR2DL5.2 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5B | killer cell immunoglobulin-like receptor two domains long cytoplasmic tail 5 | killer cell immunoglobulin-like receptor 2DLX | Killer cell immunoglobulin-like receptor 2DLX

KIR2DL5B: A Potential Drug Target for Immune and Neurodegenerative Diseases

Killer cell immunoglobulin-like receptor 2DL5B (KIR2DL5B) is a protein that is expressed in the killer cells of the human body. KIR2DL5B is a type of immunoglobulin-like receptor (ILR), which is a family of transmembrane proteins that play a crucial role in the immune system.

The KIR2DL5B protein is composed of 214 amino acid residues and has a molecular weight of 34 kDa. It is located on the surface of the killer cells and is involved in the recognition of foreign antigens.

KIR2DL5B is a receptor that is expressed in the cytoplasm of the killer cells, and its function is to recognize foreign antigens that have been processed and presented by the major histocompatibility complex (MHC) class I molecules. The MHC class I molecules are responsible for presenting antigens from the body's immune system to the T-cells, and it is the KIR2DL5B receptor that is responsible for recognizing these antigens.

Research has shown that KIR2DL5B is involved in the regulation of the immune response, and it has been identified as a potential drug target. KIR2DL5B has been shown to play a role in the regulation of the cytotoxic T-cell death, and it has been shown to be involved in the development of cancer.

In addition to its role in the immune system, KIR2DL5B has also been shown to play a role in the regulation of the blood-brain barrier. The blood-brain barrier is a barrier that separates the brain from the blood and is designed to prevent the entry of foreign substances into the brain. KIR2DL5B has been shown to be involved in the regulation of the blood-brain barrier and is thought to play a role in the development of neurodegenerative diseases.

KIR2DL5B has also been shown to be involved in the regulation of the insulin sensitivity of the body. Insulin sensitivity is the ability of the body's cells to respond to insulin, and it is an important factor in the development of type 2 diabetes. KIR2DL5B has been shown to play a role in the regulation of insulin sensitivity and is thought to be involved in the development of insulin-resistant diseases.

In conclusion, KIR2DL5B is a protein that is expressed in the killer cells of the human body and is involved in the recognition of foreign antigens. It has also been shown to play a role in the regulation of the immune system, the blood-brain barrier, and insulin sensitivity. As a result, KIR2DL5B is a potential drug target and could be useful in the development of new treatments for a variety of diseases.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 5B

Functions: Receptor on natural killer (NK) cells for HLA-C alleles. Inhibits the activity of NK cells thus preventing cell lysis

The "KIR2DL5B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR2DL5B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets